Anixa Biosciences Inc (ANIX)

Currency in USD
2.670
+0.120(+4.71%)
Closed·
2.610-0.060(-2.25%)
·
ANIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.5502.720
52 wk Range
2.3205.457
Key Statistics
Prev. Close
2.67
Open
2.55
Day's Range
2.55-2.72
52 wk Range
2.32-5.457
Volume
228.06K
Average Volume (3m)
280.89K
1-Year Change
-34.878%
Book Value / Share
0.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.667
Upside
+262.05%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Anixa Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.667
(+262.05% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy6.00+124.72%-Maintain06/10/2026
H.C. Wainwright
Buy6.00+124.72%7.00Maintain23/09/2026
H.C. Wainwright
Buy7.00+162.17%-Maintain12/06/2026

Earnings

Latest Release
11/09/2026
EPS / Forecast
-0.08 / -0.08
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ANIX Income Statement

Compare ANIX to Peers and Sector

Metrics to compare
ANIX
Peers
Sector
Relationship
P/E Ratio
−8.9x−1.7x−0.2x
PEG Ratio
−0.85−0.040.00
Price/Book
6.4x2.1x2.6x
Price / LTM Sales
-5.8x2.7x
Upside (Analyst Target)
262.0%175.2%68.5%
Fair Value Upside
Unlock13.5%11.5%Unlock

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.95M5.60%4.96M
Other Institutional Investors
3.45M9.92%8.80M
Public Companies & Retail Investors
29.37M84.48%74.89M
Total
34.76M100.00%88.65M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC4.38%1,522,2083,882
Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF2.70%936,9272,389

People Also Watch

14.24
NRIX
-3.33%
63.65
ETON
-0.36%
23.68
INVX
-1.46%
96.80
KOD
-3.90%
1.020
CABA
-8.11%

FAQ

What Is the Anixa Biosciences (ANIX) Stock Price Today?

The Anixa Biosciences stock price today is 2.670 USD.

What Stock Exchange Does Anixa Biosciences Trade On?

Anixa Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Anixa Biosciences?

The stock symbol for Anixa Biosciences is "ANIX."

What Is the Anixa Biosciences Market Cap?

As of today, Anixa Biosciences market cap is 92.820M USD.

What Is Anixa Biosciences's Earnings Per Share (TTM)?

The Anixa Biosciences EPS (TTM) is -0.31.

When Is the Next Anixa Biosciences Earnings Date?

Anixa Biosciences will release its next earnings report on 06/01/2027.

From a Technical Analysis Perspective, Is ANIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Anixa Biosciences Stock Split?

Anixa Biosciences has split 5 times.

How Many Employees Does Anixa Biosciences Have?

Anixa Biosciences has 4 employees.

What is the current trading status of Anixa Biosciences (ANIX)?

As of 18/11/2026, Anixa Biosciences (ANIX) is trading at a price of 2.670 USD, with a previous close of 2.670 USD. The stock has fluctuated within a day range of 2.550 USD to 2.720 USD, while its 52-week range spans from 2.320 USD to 5.457 USD.

What Is Anixa Biosciences (ANIX) Price Target According to Analysts?

The average 12-month price target for Anixa Biosciences is 9.667 USD, with a high estimate of 14 USD and a low estimate of 6 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +262.05% Upside potential.

What Is the ANIX Premarket Price?

ANIX's last pre-market stock price is 2.700 USD. The pre-market share volume is 10.000, and the stock has decreased by 0.150, or 5.880%.

What Is the ANIX After Hours Price?

ANIX's last after hours stock price is 2.610 USD, the stock has decreased by -0.060, or -2.250%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.